DTG/3TC vs B/F/TAF for HIV: Similar virologic efficacy at 96 weeks
04 Dec 2025
bởiElaine Soliven
Switching to dolutegravir/lamivudine (DTG/3TC) or continuing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) showed comparable virologic efficacy through 96 weeks in adults with HIV infection, according to the DYAD observational, open-label extension (OLE) study presented at IDWeek 2025.